Navigation Links
Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA

EDP-322 is a First-in-class MRSA-active Bicyclolide, a novel

macrolide-related drug class

WATERTOWN, Mass., Sept. 15 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced today the initiation of a Phase 1 study on investigational oral antibiotic EDP-322, a first-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class with a distinct resistance profile. The clinical development program for EDP-322 will include the treatment of hospital- and community-acquired gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Preclinically, EDP-322 has demonstrated strong in vitro activity against hospital-acquired MRSA strains resistant to vancomycin, Zyvox(R) (linezolid), and CUBICIN(R) (daptomycin).

"Macrolides have been commonly prescribed to treat community infections for decades due to their convenient oral dosing and favorable safety profile," said Robert Moellering, M.D., a professor of medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. "Now with the discovery of a new generation of macrolides having high potency against hospital-acquired pathogens and a distinct resistance profile relative to other hospital antibiotics, there is a tremendous new opportunity to explore their use within not only the community, but the hospital setting as well."

"In our in vitro studies, EDP-322 demonstrated good potency against both hospital- and community-acquired MRSA, even against highly drug-resistant MRSA strains," explained Yat Sun Or, Ph.D., Senior Vice President of Research and Development at Enanta. "The potency of EDP-322 against hospital-acquired MRSA, community-acquired MRSA, and other gram-positive pathogens, combined with the convenience of oral administration, has the potential to uniquely position EDP-322 among marketed MRSA drugs in both the hospital and community settings."

Phase 1a Study Design

The Phase 1a, double-blind, placebo controlled study for EDP-322 announced today is a single ascending dose trial in healthy volunteers.

About Enanta's Bicyclolide Research Program

Bicyclolides posses a reengineered back-bone structure of traditional macrolide antibiotics. The discovery of Bicyclolide effectiveness against MRSA and VRE infections is part of Enanta's broad antibiotic research program. Enanta has applied several research strategies to develop these new classes of antibiotics, including innovative medicinal chemistry approaches to create novel and proprietary chemical structures. Enanta has applied its chemistry approach to create a promising pipeline of anti-infective drugs and a vast intellectual property estate.

About MRSA

More than 130,000 people each year need hospital care for MRSA infections, according to the Centers for Disease Control and Prevention. Staphylococcus aureus is a bacterium that can live harmlessly on human skin and is found in the nose of 20 to 40 percent of healthy individuals, but can sometimes cause infections when exposed to broken skin. MRSA is a particular type of the bacteria that has developed resistance to many antibiotics, including methicillin, making it difficult to treat.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field. At the heart of Enanta is its commitment to innovative chemistry that surpasses traditional medicinal chemistry approaches. Enanta is developing novel protease, polymerase, and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA. Enanta is a privately held company with offices in Watertown, MA. More information about the company can be found at

Zyvox is a registered trademark of Pfizer Inc. and CUBICIN is a registered trademark of Cubist Pharmaceuticals, Inc.

Enanta Contacts

For Enanta Investor Relations, please contact:

Paul Mellett


For Enanta Public Relations, please contact MacDougall Biomedical Communications:

Kari Watson


SOURCE Enanta Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
3. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
7. Isis Initiates Clinical Trial of CRP Drug
8. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
9. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
10. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
11. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Post Your Comments:
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
Breaking Medicine News(10 mins):